The technological revolution behind this reframing is worth appreciating. For most of the history of cancer biology, fibroblasts were studied in bulk, and their heterogeneity was invisible. The advent of single-cell RNA sequencing allowed researchers to profile the gene expression of individual fibroblasts within a tumor, revealing a startling mosaic of states. Spatial transcriptomics then added geography to the picture, showing where each fibroblast subtype resides relative to cancer cells, blood vessels, and immune cells. Multi-omics approaches that layer epigenetic, proteomic, and metabolic data on top of these maps have now made it possible to trace how fibroblast identities shift as tumors evolve. What has emerged is a taxonomy of recurring CAF programs: myofibroblastic CAFs marked by alpha-smooth muscle actin and contractile machinery, inflammatory CAFs that secrete cytokines such as interleukin-6 and CXCL12, antigen-presenting CAFs that display MHC class II molecules, interferon-response CAFs, and vascular-associated CAFs that hug the tumor’s blood supply.

Each of these states maps onto specific steps of the metastatic cascade, the multi-stage journey that carries a tumor cell from its primary site to a distant organ. The first step, local invasion, depends heavily on extracellular matrix remodeling. Myofibroblastic CAFs are master builders and demolition crews of the matrix, depositing collagen and cross-linking it with enzymes such as lysyl oxidase. This stiffened, realigned matrix does not merely form a physical scaffold; it generates mechanical cues that activate signaling pathways like FAK, YAP/TAZ, and ROCK in neighboring cancer cells, promoting epithelial-mesenchymal transition, the program by which epithelial tumor cells acquire motile, invasive properties. In pancreatic ductal adenocarcinoma, one of the most fibroblast-dense malignancies known, this dense stroma creates both a barrier to immune infiltration and a highway for invasion, illustrating how a single fibroblast program can simultaneously enable multiple metastatic steps.

Once tumor cells begin to move, they must evade the immune system, and here the review highlights a particularly insidious role for inflammatory CAFs. Through secretion of chemokines such as CXCL12 and CCL5, these fibroblasts recruit immunosuppressive cells, including regulatory T cells and myeloid-derived suppressor cells, while excluding or exhausting cytotoxic T lymphocytes that would otherwise kill tumor cells. The JAK/STAT and NF-kappa-B signaling pathways are central to this inflammatory choreography. Antigen-presenting CAFs add another layer of complexity: by expressing MHC class II molecules and, in some contexts, immune checkpoints such as PD-L2, they can directly modulate T cell activity in ways that remain incompletely understood but appear to tilt the local immune balance toward tolerance rather than attack. The net effect is a tumor microenvironment in which the stroma itself acts as an immunological shield.

Angiogenesis and vascular dissemination represent the next stage of the journey, and vascular-associated CAFs sit at this frontier. Positioned adjacent to tumor blood vessels, these cells interact with endothelial cells through vascular endothelial growth factor signaling and other pathways, supporting the formation of the leaky, disorganized vasculature that allows circulating tumor cells to enter the bloodstream. The review also describes how fibroblasts contribute to pre-metastatic niche formation, a phenomenon in which the primary tumor sends molecular advance parties, often packaged in extracellular vesicles, to distant organs such as the lung, liver, and bone. These signals condition resident fibroblasts in future metastatic sites, prompting them to remodel the matrix, secrete inflammatory mediators, and lay down a welcoming bed before any cancer cell arrives. Neutrophil extracellular traps and other stromal components recruited in this process further prepare distant tissues for colonization.

Metastatic colonization, the final and often fatal step, is where fibroblast support may matter most. Circulating tumor cells that survive in the bloodstream face a hostile foreign microenvironment, and the success or failure of their settlement depends on the stromal soil they encounter. The review emphasizes that the relationship between CAF states and metastatic progression is bidirectional: not only do distinct fibroblast states regulate specific steps of the cascade, but tumor-derived cues, inflammation, vascular signals, mechanical stress, metabolic conditions, and even therapy itself can reshape the composition and behavior of the fibroblast population. Chemotherapy, for example, can induce fibroblast state transitions that render the microenvironment more permissive to regrowth, a form of therapy-induced plasticity that may explain some treatment failures.

Perhaps the most consequential message of the review concerns the context-dependent duality of CAF function. Fibroblasts are not uniformly villainous. Certain fibroblast states and signals have been shown to restrain tumor growth, maintain tissue architecture, and support anti-tumor immunity. The authors point to clinical lessons from attempts at indiscriminate stromal depletion: in some settings, eliminating fibroblasts or blocking their hallmark signaling pathways worsened outcomes, unleashing more aggressive tumor behavior. The Sonic hedgehog pathway in pancreatic cancer became a cautionary tale in this regard, as its inhibition depleted stroma yet failed to improve, and in some models worsened, disease. Vitamin D receptor signaling, by contrast, has been associated with a tumor-restraining fibroblast phenotype, suggesting that reprogramming fibroblasts toward benign states may be more productive than killing them.

This insight underpins the precision therapeutic strategies the review advocates. Rather than viewing the stroma as a target for demolition, the authors propose selective modulation: identifying which fibroblast states dominate a given tumor, at a given metastatic stage, and intervening to disable their tumor-promoting functions while preserving or enhancing their tumor-restraining ones. Candidate approaches include inhibiting fibroblast activation protein on specific CAF subsets, blocking TGF-beta signaling in myofibroblastic CAFs, reprogramming inflammatory CAFs through agents such as all-trans retinoic acid, and exploiting metabolic vulnerabilities unique to particular fibroblast states. Emerging technologies such as CAR-T cells engineered against CAF-specific antigens and photodynamic therapy aimed at stromal compartments are also evaluated, with the authors stressing that each strategy must account for the risk of pushing plastic fibroblasts into more dangerous states.

The framework proposed by Li and colleagues integrates four dimensions that have often been studied in isolation: cellular state, spatial niche, metastatic stage, and phenotypic plasticity. In this view, a myofibroblastic CAF at the invasive front of a primary tumor, an inflammatory CAF clustered near excluded T cells, and a vascular-associated CAF lining a metastatic niche in the liver are not variations on a theme but distinct therapeutic targets requiring distinct interventions. The authors acknowledge that major questions remain unresolved, including how the reciprocal feedback loops between tumor cells and fibroblasts determine therapeutic response, and how best to monitor CAF state composition in patients over time. Single-cell and spatial technologies are increasingly being applied to clinical samples, raising the prospect that fibroblast-state profiling could one day guide stromal-targeted treatment decisions just as molecular profiling of tumor cells guides targeted therapy today.

For a field that has spent decades focused almost exclusively on the cancer cell itself, the message of this synthesis is quietly radical: the most abundant cell in many tumors is not a passive bystander but an active, plastic, and heterogeneous participant in metastasis, and the tools to map and manipulate it are finally at hand. If the metastasis-oriented framework proposed here proves correct, the future of anti-metastatic therapy may depend less on attacking tumor cells directly and more on negotiating with the fibroblasts that build their roads, guard their borders, and prepare their landing sites. Turning these cellular accomplices from collaborators into inhibitors, the review suggests, could transform how medicine confronts the spread of cancer, the process responsible for the majority of cancer deaths worldwide.

Subject of Research: Heterogeneity of cancer-associated fibroblasts and their roles in tumor metastasis and targeted therapy

Article Title: Heterogeneity of cancer-associated fibroblasts in tumor metastasis: mechanisms and precision therapeutic strategies

Article References: Li, Y., Chen, Y., Shen, X., Lou, J., Zhang, L., Qin, J., Pan, Y., & Wang, S. (2026). Heterogeneity of cancer-associated fibroblasts in tumor metastasis: mechanisms and precision therapeutic strategies. Molecular Cancer. https://doi.org/10.1186/s12943-026-02805-4

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02805-4

Keywords: cancer-associated fibroblasts, tumor metastasis, tumor microenvironment, extracellular matrix remodeling, single-cell RNA sequencing, spatial transcriptomics, pre-metastatic niche, epithelial-mesenchymal transition, angiogenesis, immune evasion, CAF plasticity, stromal-targeted therapy